Cargando…

A Novel Prognostic Ferroptosis-Related Long Noncoding RNA Signature in Clear Cell Renal Cell Carcinoma

Clear cell renal cell carcinoma (ccRCC) is the most common primary malignancy of renal cancer in adults. Ferroptosis is critically associated with the prognosis of ccRCC. However, knowledge of long noncoding RNA- (lncRNA-) related ferroptosis that affects the prognosis of ccRCC is still insufficient...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Zhixun, Zhao, Yongchao, Yang, Xiaomin, Wang, Linglu, Yin, Xianhua, Chen, Yue, Lu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888116/
https://www.ncbi.nlm.nih.gov/pubmed/35242188
http://dx.doi.org/10.1155/2022/6304824
_version_ 1784661062660915200
author Bai, Zhixun
Zhao, Yongchao
Yang, Xiaomin
Wang, Linglu
Yin, Xianhua
Chen, Yue
Lu, Jing
author_facet Bai, Zhixun
Zhao, Yongchao
Yang, Xiaomin
Wang, Linglu
Yin, Xianhua
Chen, Yue
Lu, Jing
author_sort Bai, Zhixun
collection PubMed
description Clear cell renal cell carcinoma (ccRCC) is the most common primary malignancy of renal cancer in adults. Ferroptosis is critically associated with the prognosis of ccRCC. However, knowledge of long noncoding RNA- (lncRNA-) related ferroptosis that affects the prognosis of ccRCC is still insufficient. Using the LASSO regression, we created a risk model based on differentially expressed ferroptosis-related lncRNAs (FRLRS) in ccRCC. The analysis of Kaplan–Meier for survival, area under the curve (AUC) for diagnosis, nomogram for predicting overall survival, and gene expression for immune checkpoints were performed based on the screened independent prognostic factors. Nine lncRNAs were found to be associated with ccRCC prognosis. Furthermore, the prognostic AUC of the FRLRS signature was 0.78, demonstrating its usefulness in predicting ccRCC prognosis. The lncRNA risk model outperformed the standard clinical variables in predicting ccRCC prognosis. Finally, The Cancer Genome Atlas revealed that T cell functions, such as cytolytic activity, human leukocyte antigen activity, inflammation regulation, and type II interferon response coordination, are significantly different between two different risk levels of ccRCC. Immune checkpoints were also expressed differently in programmed cell death 1 receptor, inducible T cell costimulator, cytotoxic T-lymphocyte antigen-4, and leukocyte-associated immunoglobulin-like receptor 1. The nine FRLRS signature models may affect the prognosis of ccRCC.
format Online
Article
Text
id pubmed-8888116
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-88881162022-03-02 A Novel Prognostic Ferroptosis-Related Long Noncoding RNA Signature in Clear Cell Renal Cell Carcinoma Bai, Zhixun Zhao, Yongchao Yang, Xiaomin Wang, Linglu Yin, Xianhua Chen, Yue Lu, Jing J Oncol Research Article Clear cell renal cell carcinoma (ccRCC) is the most common primary malignancy of renal cancer in adults. Ferroptosis is critically associated with the prognosis of ccRCC. However, knowledge of long noncoding RNA- (lncRNA-) related ferroptosis that affects the prognosis of ccRCC is still insufficient. Using the LASSO regression, we created a risk model based on differentially expressed ferroptosis-related lncRNAs (FRLRS) in ccRCC. The analysis of Kaplan–Meier for survival, area under the curve (AUC) for diagnosis, nomogram for predicting overall survival, and gene expression for immune checkpoints were performed based on the screened independent prognostic factors. Nine lncRNAs were found to be associated with ccRCC prognosis. Furthermore, the prognostic AUC of the FRLRS signature was 0.78, demonstrating its usefulness in predicting ccRCC prognosis. The lncRNA risk model outperformed the standard clinical variables in predicting ccRCC prognosis. Finally, The Cancer Genome Atlas revealed that T cell functions, such as cytolytic activity, human leukocyte antigen activity, inflammation regulation, and type II interferon response coordination, are significantly different between two different risk levels of ccRCC. Immune checkpoints were also expressed differently in programmed cell death 1 receptor, inducible T cell costimulator, cytotoxic T-lymphocyte antigen-4, and leukocyte-associated immunoglobulin-like receptor 1. The nine FRLRS signature models may affect the prognosis of ccRCC. Hindawi 2022-02-22 /pmc/articles/PMC8888116/ /pubmed/35242188 http://dx.doi.org/10.1155/2022/6304824 Text en Copyright © 2022 Zhixun Bai et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bai, Zhixun
Zhao, Yongchao
Yang, Xiaomin
Wang, Linglu
Yin, Xianhua
Chen, Yue
Lu, Jing
A Novel Prognostic Ferroptosis-Related Long Noncoding RNA Signature in Clear Cell Renal Cell Carcinoma
title A Novel Prognostic Ferroptosis-Related Long Noncoding RNA Signature in Clear Cell Renal Cell Carcinoma
title_full A Novel Prognostic Ferroptosis-Related Long Noncoding RNA Signature in Clear Cell Renal Cell Carcinoma
title_fullStr A Novel Prognostic Ferroptosis-Related Long Noncoding RNA Signature in Clear Cell Renal Cell Carcinoma
title_full_unstemmed A Novel Prognostic Ferroptosis-Related Long Noncoding RNA Signature in Clear Cell Renal Cell Carcinoma
title_short A Novel Prognostic Ferroptosis-Related Long Noncoding RNA Signature in Clear Cell Renal Cell Carcinoma
title_sort novel prognostic ferroptosis-related long noncoding rna signature in clear cell renal cell carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888116/
https://www.ncbi.nlm.nih.gov/pubmed/35242188
http://dx.doi.org/10.1155/2022/6304824
work_keys_str_mv AT baizhixun anovelprognosticferroptosisrelatedlongnoncodingrnasignatureinclearcellrenalcellcarcinoma
AT zhaoyongchao anovelprognosticferroptosisrelatedlongnoncodingrnasignatureinclearcellrenalcellcarcinoma
AT yangxiaomin anovelprognosticferroptosisrelatedlongnoncodingrnasignatureinclearcellrenalcellcarcinoma
AT wanglinglu anovelprognosticferroptosisrelatedlongnoncodingrnasignatureinclearcellrenalcellcarcinoma
AT yinxianhua anovelprognosticferroptosisrelatedlongnoncodingrnasignatureinclearcellrenalcellcarcinoma
AT chenyue anovelprognosticferroptosisrelatedlongnoncodingrnasignatureinclearcellrenalcellcarcinoma
AT lujing anovelprognosticferroptosisrelatedlongnoncodingrnasignatureinclearcellrenalcellcarcinoma
AT baizhixun novelprognosticferroptosisrelatedlongnoncodingrnasignatureinclearcellrenalcellcarcinoma
AT zhaoyongchao novelprognosticferroptosisrelatedlongnoncodingrnasignatureinclearcellrenalcellcarcinoma
AT yangxiaomin novelprognosticferroptosisrelatedlongnoncodingrnasignatureinclearcellrenalcellcarcinoma
AT wanglinglu novelprognosticferroptosisrelatedlongnoncodingrnasignatureinclearcellrenalcellcarcinoma
AT yinxianhua novelprognosticferroptosisrelatedlongnoncodingrnasignatureinclearcellrenalcellcarcinoma
AT chenyue novelprognosticferroptosisrelatedlongnoncodingrnasignatureinclearcellrenalcellcarcinoma
AT lujing novelprognosticferroptosisrelatedlongnoncodingrnasignatureinclearcellrenalcellcarcinoma